Abstract:737 Background: The standard of care for patients with moderate or high-risk resectable gastrointestinal stromal tumors (GIST) is surgical resection followed by adjuvant therapy with imatinib. The impact of neoadjuvant imatinib on long-term outcomes is largely unknown. Methods: We interrogated the LifeRaft registry, a large international open cohort of patients with GIST. We included patients who did not have metastatic disease at diagnosis, underwent surgical resection and received neoadjuvant imatinib and had no recorded mutations of Kit exon 13 or PDGFRA exon 18 D842V. Baseline patient characteristics were described and survival probabilities were estimated and plotted using the Kaplan-Meier method. Cox regression was used to estimate the effect of demographic and clinical characteristics on recurrence-free survival (RFS) and overall survival (OS). For RFS, time was calculated from the date of surgery to disease recurrence/death, whichever came first. For OS, time was calculated from the date of surgery to death. Estimated effects of predictors were reported as hazard ratios (HR) along with 95% confidence intervals (CI). All statistical testing was two-sided and assessed for significance at the 5% level using SAS v9.4 (SAS Institute, Cary, NC). Results: Out 2,472 patients with GIST, 137 patients met the inclusion criteria and received neoadjuvant imatinib for a median of 6.8 months. Majority of the patients were aged 40 years or above (129/137, 94.2%) and were males (73/137, 53.3%). The majority of the patients had gastric GIST (72/137, 54.1%), followed by small intestine GIST (34/137, 25.6%) and other (27/137, 20.3%). Most patients had a tumor size of >10 cm (66/137, 52.4%) at the time of diagnosis followed by >5 cm - 2 cm - <=5 cm (18/137, 14.3%). The median RFS for the cohort was 6.1 years. On multivariable analysis, tumor size (HR 1.08, 95% CI 1.05-1.12, p<0.01) and the overall duration of treatment (neoadjuvant and adjuvant) with imatinib therapy (HR 0.98, 95% CI 0.97-0.99, p<0.01) were significantly associated with RFS. A 1-cm increase in tumor size and 1-month increase in total time on imatinib was associated with an 8% increase and 2% decrease in risk of recurrence. The median OS was 14.2 years. Female gender (HR 0.23 95% CI 0.08-0.65, p<0.01) and total length of time on imatinib (HR 0.97 95% CI 0.96-0.99, p 10 cm. Smaller tumor size and female gender predicted longer RFS and OS respectively. Longer total duration of imatinib therapy was associated with increased RFS and OS.

Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability

To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.

Impact of Kit and Pdgfra Gene Mutations on Prognosis of Patients with Gastrointestinal Stromal Tumors after Complete Primary Tumor Resection

The management of metastatic GIST: current standard and investigational therapeutics

Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor

The role of KIT in the management of patients with gastrointestinal stromal tumors

Precision Oncology in Gastrointestinal Stromal Tumors

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

Mutational Characteristics of Gastrointestinal Stromal Tumors: A Single-Center Analysis of 302 Patients

KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape

Preclinical model-based evaluation of Imatinib resistance induced by <i>KIT</i> mutations and its overcoming strategies in gastrointestinal stromal tumor (GIST)

A systematic review and meta‐analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors

[Gastrointestinal stromal tumors : Where do we stand?]

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours

Characteristics and predictors of outcomes with neoadjuvant imatinib in gastrointestinal stromal tumors: Real-world data from a large patient registry.

Preclinical model-based evaluation of Imatinib resistance induced by KIT mutations and its overcoming strategies in gastrointestinal stromal tumor (GIST)

Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research

C-KIT Mutations Were Closely Associated with the Response to Imatinib in Chinese Advanced Gastrointestinal Stromal Tumor Patients.

Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor

[Secondary Mutation of C-Kit/pdgfrα Genotypes after Imatinib Mesylate Therapy and Its Relationship with Efficacy of Sunitinib].

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges